Lates News

Every AI Express, Puyin International Securities released a research report on November 3, giving Rongchang Bio (688331.SH) a "hold" rating. The rating reasons mainly include: 1) 3Q25 product revenue and net loss attributable to the mother are slightly better than our expectations; 2) The commercial performance of Taietasip in the third quarter is slightly better than expected, and the Videxiwestu monoclonal antibody meets expectations; it is suggested to pay attention to the results of medical insurance negotiations for two drugs recently; 3) RC148 (PD-1/VEGF) research and development is ongoing, and 1L 2LNSCLC will be prioritized for advancement. (Daily Economic News)